Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

BACKGROUND: An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3 study, ipilimumab — which blocks cytotoxic T-lymphocyte–associated antigen 4 to potentiate an antitumor T-cell response — administered with or without a glycoprotein 100 (...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Hodi, F. Stephen, O’Day, Steven J., McDermott, David F., Weber, Robert W., Sosman, Jeffrey A., Haanen, John B., Gonzalez, Rene, Robert, Caroline, Schadendorf, Dirk, Hassel, Jessica C., Akerley, Wallace, van den Eertwegh, Alfons J.M., Lutzky, Jose, Lorigan, Paul, Vaubel, Julia M., Linette, Gerald P., Hogg, David, Ottensmeier, Christian H., Lebbé, Celeste, Peschel, Christian, Quirt, Ian, Clark, Joseph I., Wolchok, Jedd D., Weber, Jeffrey S., Tian, Jason, Yellin, Michael J., Nichol, Geoffrey M., Hoos, Axel, Urba, Walter J.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2010
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3549297/
https://ncbi.nlm.nih.gov/pubmed/20525992
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1003466
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items